The efficacy and safety of Oxaliplatin-Vinorelbine as a second-line chemotherapy combination in patients with platinum-resistant pretreated epithelial ovarian cancer: A retrospective study by Mumtahana, Fidia et al.
International Journal of Cancer Therapy and Oncology
www.ijcto.org
Corresponding author: Baoxia Cui; Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, Shandong Province, China.
Cite this article as: Mumtahana F, Tian X, Zhang T, Cui B. The efficacy and safety of Oxaliplatin-Vinorelbine as a second-line chemotherapy combination in
patients with platinum-resistant pretreated epithelial ovarian cancer: A retrospective study. Int J Cancer Ther Oncol 2014; 2(4):020413.
DOI: 10.14319/ijcto.0204.13
© Mumtahana et al. ISSN 2330-4049
The efficacy and safety of Oxaliplatin-Vinorelbine as a
second-line chemotherapy combination in patients with
platinum-resistant pretreated epithelial ovarian cancer: A
retrospective study
Fidia Mumtahana, Xinli Tian, Teng Zhang, Baoxia Cui
Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, Shandong Province, China
Received September 09, 2014; Revised October 08, 2014; Accepted October 09, 2014; Published Online October 10, 2014
Original Article
Abstract
Purpose: The main purpose of this study was to analyze the effects and tolerability of Oxaliplatin-Vinorelbine combination on
Platinum-resistant epithelial ovarian carcinoma (EOC) patients. Methods: A single centered retrospective study comprising of 34
patients was conducted, and all 34 patients were treated with Vinorelbine 30 mg/m2 on day 1 and 8 along with Oxaliplatin 100
mg/m2on day 1 of 3 weeks treatment cycle following progressive platinum-resistant EOC. Results: The combination showed an
overall response rate (ORR) of 18% (95% CI, 4.4 - 31.6) where 2 (6%) patients had complete response and 4 (12%) patients had
partial response. Stable disease was observed in 9 (26%) patients and progressive disease in 19 (56%) patients. Median diseases free
survival, median relapse free survival and median time to progression was 17.05 months, 4.4 months, and 1.25 months, respec-
tively. Hematological toxicities were mild; only 1 (2.9%) patient had G3 anemia and major non-hematological toxicities include
nausea-vomiting, diarrhea, constipation, hepatotoxicity, fatigueness and alopecia, which are mainly limited to G1-G2 and re-
versible. Conclusion: The effect of this combination is moderate as a second line treatment of platinum resistant EOC; however,
in comparison with other regimens of Vinorelbine and Oxaliplatin, the activity is substandard but the toxicity profile is well
tolerable. Further multicenter evaluation is needed for the better understanding of the therapeutic efficacy of the combination.
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Introduction
Ovarian cancer is the most fatal gynecologic carcinoma
around the world.1, 2 Approximately 225,000 women are
diagnosed for ovarian cancer per year and there is record of
almost 1, 40,000 deaths worldwide out of this disease.3, 4
Symptoms of the disease are not significant which may mimic
other diseases conditions and cause delayed diagnosis.5 The
majority of the women about 75% are diagnosed with ad-
vanced stage diseases that are FIGO III or IV and overall
survival rate for 5 years is about 40%.6-10 The application of
cytoreductive surgery followed by platinum-based chemo-
therapy, with or without the addition of a taxane is the most
accepted treatment for advanced EOC.3, 11, 12 Record reveals
that approximately 75% of these patients attain complete
clinical remission after the initial treatment.4 Despite this
fact, the majority of women with advanced EOC will ulti-
mately relapse and 20% of these patients with platinum- and
taxane-resistant disease.13-16 Cases of recurrences within 6
months following an initial response to platinum-based
treatment or patients with stable disease during Plati-
num-based therapy are recognized as having plati-
num-resistant EOC.17 These very particular patients experi-
ence poor outcome and deserve to extend their survival ex-
pectancy with relieved symptoms with a better quality of
life.13 So there is a necessity of second- line treatment to be
administered for better physiological function and desired
level of performance. At present diversive active second - line
agents are available for ovarian cancer treatment and clini-
cians are using these frequently.15 But the result of these
second-line treatments on survival is usually not upto the
mark.18 Single as well as combination chemotherapy regimens
are being used for the above mentioned patients. However,
these regimens seem to cause greater level of toxicity without
enhancing its efficacy.19, 20
Oxaliplatin (OXL) is a platinum derivative, diaminocyclo-
hexane platinum which has exhibited activities contrary to
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different types of tumors with a symmetrical mechanism of
impact like that of classic platinum drugs showing a differ-
ent toxicity  profile. Cisplatin or carboplatin seem not to be
cross-resistant with OXL in human ovarian cell lines. A range
of 16 - 29% is the response rate of oxaliplatin as a single acting
agent.4, 21, 22 Clinical result reveals no significant renal or
auditive toxicity with oxaliplatin in recommended dose but
marginally hematotoxicity being noticed. Acute
cold-triggered dysesthesias with parasethesia and cumulative
neurosensorial toxicity is the major frequent side effects of
oxaliplatin.23-25
Vinorelbine (VNR) (5’-noranhydrovinblastine) is a semi
synthetic anticancer agent derived from Vinca alkaloid group
that exhibits an improved toxicity profile than vincristine and
other Vinca alkaloid analogues and effective activity against
advanced EOC.26, 27 Application of VNR alone to patients with
heavily pre-treated and platinum-resistant EOC has shown a
21% response rate.28, 29 VNR projects a reduced level of neu-
rotoxicity but causes a greater level of haematological tox-
icity.30, 31
Basing on the above mentioned information we decided to
conduct a retrospective study on platinum pre-treated re-
current EOC patients to determine the efficacy and evaluate
the toxicity of the combination of OXL-VNR regimen that is
used in routine practice. To the best of our knowledge, there
are not so much of studies available to determine the effects
of this combination on platinum-resistant EOC patients.
Patients and Methods
Patients
Patient’s data for this retrospective study was collected from
the at the Department of Gynecology of Qilu Hospital of
Shandong Medical University, China between July 2009 and
March 2014.
Approval of the study was obtained from the local ethical
committees and was conducted in accordance with the Dec-
laration of Helsinki and Good Clinical Practice Guidelines.
The patient inclusion criteria: a) Histologically confirmed
EOC; b) Relapsing disease within 6 months after plati-
num-containing combination therapy or progressive diseases
while on treatment with measurable lesion (evidenced by
imaging methods); c) Previously not treated with either OXL
or VNR; d) Evidence of no other serious illness; e) Detailed
clinicopathologic data and follow-up data. Medical records
served with all the clinical information for every patient.
Diseases status and required important data concerning the
patients including tumor recurrence and patient death were
provided from routinely maintained hospital registry.
TABLE 1: Patient characteristics.
Characteristics No. of patients(n) Percentage %










Clear cell 2 6
Mucinous 1 3
Unknown 2 6
Poorly differentiated 3 9
Stage at diagnosis
III C 34 100
The patient exclusion criteria: a) Previous chemotherapy was
not incorporated with platinum; b) Increased level of CA -125
was considered as the only indication of relapsing diseases; c)
Having central nervous system metastasis; d) previous or
existing carcinoma other than the ovarian.
A total 34 patients, aged between 32 and 73 years diagnosed
with EOC and resistant to platinum based first line chemo-
therapy agents who were admitted in our department in
above mentioned period and fulfilled the inclusion criteria
are enrolled in this study. All the patients were diagnosed at
FIGO stage IIIC. Table 1 comprises the patient characteristics.
Prior to the administration of VNR-OXL regimen all the
patients were administered with 234 Platinum derivative
chemotherapy cycles (Table 2) with a median number of 2
cycles (range 1 to 8).
TABLE 2: Previous Platinum based chemotherapy regimen charac-
teristics.











Cisplatin+Cyclophosphamide 10 70 (30%)
Carboplatin+Paclitaxel 13 65 (27.9%)
Carboplatin+Docetaxel 5 35 (15%)
Cisplatin+Paclitaxel 7 24 (10.30%)
Cisplatin+ Docetaxel 3 15 (6.43%)
Cisplatin+Topotecan 4 14 (6%)
Lobaplatin+Docetaxel 1 6 (2.57%)
Carboplatin+Topotecan 1 4 (1.7%)
Cisplatin+5FU 1 1 (0.43%)
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Prior to the treatment administration all eligible patients
were confirmed with diseases relapse by evaluating clinical
examination, serological tests and imaging modules.
Given treatment
VNR 30 mg/m2 was diluted in 100 ml normal saline and ad-
ministered as a 15 minutes intravenous infusion on days 1 and
8 of every 21-day treatment cycle. Again OXL 100 mg/m2
diluted in 500 ml of 5% glucose solution and given as an
intravenous infusion over 2 hours on day 1 which had started
15 minutes after the end of day 1 VNR administration. G-CSF
was given prophylactically on days 12-16. All patients got
standard antiemetic drugs and corticosteroids. Cycles were
repeated every 3 weeks and treatment was continued unless
diseases progression, toxicities were uncontrolled by con-
servative treatment. For an obvious delayed treatment, 25%
dosage for both drugs in subsequent cycles needed to be
minimized.
Treatment characteristics of VNR-OXL regimen are shown in
Table 3. A total 108 cycles of chemotherapy (with a median of
3) were administered. Median interval from previous treat-
ment was 3.6 months (range: 0.7- 5.5 months). During the
course of this regimen no treatment-related death was ob-
served.
TABLE 3: Treatment characteristics.
Characteristics
Interval from previous treatment (months)
Median 3.6











No. of cycles received by patients No. of patients
1-3 cycles 18 (53%)
4-5 cycles 11 (32.3%)
6-7 cycles 5(14.7%)
Percentage of cycles with full dose for both drugs 82
Percentage of cycles with delay (>24 days) 26




Prior to each course, patient’s history and clinical examina-
tion with assessment of evaluable lesions, performance status,
complete blood count along with other blood biochemistries
(serum creatinine, serum bilirubin, AST, ALT, Alkaline
phosphatase, serum electrolytes, calcium, magnesium, serum
protein levels, Ca 125 assay) and ECG were performed.
Complete blood counts were done every weekly to assess the
hematological toxicity, while imaging modules were carried
out every three cycles for lesion assessment.
To determine the response rate and toxicity of the treatment
World Health Organization (WHO) criteria for treatment
response and toxicity were applied.32 The Kaplan-Meier
method was selected for statistical analysis to determine me-
dian and confidence interval and for other data analysis.
Results
Toxicity
All the patients were evaluable for toxicity which is shown in
Table 4. The main toxicity includes hematological toxicities,
nausea-vomiting, diarrhea, constipation, hepatotoxicity,
alopecia and fatigueness. 44% of the patients had anemia and
among this G1 was commonly seen (29.4%). 44% and 35.3%
patients had Leukopenia and neutropenia respectively which
remain within G1 and G2. 70.6% patients suffered from
nausea and vomiting but mainly G1(61.8%). Diarrhea and
constipation were observed in 41.15% and 32.2% patients
respectively and in both G1 was common. 61.6% patient had
alopecia but limited mainly within G1 and G2. Hepatotoxi-
city and fatigueness were seen in 32.2 % (mainly G1) and 32.4
% (G2) patients respectively.
The minor toxicities were thrombocytopenia, febrile neu-
tropenia, cardiac toxicity, nephrotoxicity, neurotoxicity,
infections and skin rash which are mainly seen with G1 and
G2. However, no toxicity reached to the level of G4. Due to
hematological or extra-hematological toxicities 6 (17.6%)
patients had delayed treatment and 4 (12%) had to go through
dose reduction.
TABLE 4: Toxicity percentage in patients.
Toxicity Grade I Grade II Grade III Grade IV
Anemia 10(29.4%) 4(11.8%) 1(2.9%)
Leukopenia 13(38.2%) 2(5.8%) - -
Neutropenia 7(20.6%) 5(14.7%) - -
Thrombocytopenia 8(23.5%) - - -
Febrile neutropenia 1(2.9%) 3(8.8%) - -
Nausea / Vomiting 18 (53%) 3(8.8%) 3(8.8%) -
Diarrhoea 11(32.35%) 3(8.8%) - -
Constipation 8(23.5%) 2(5.8%) 1(2.9%) -
Hepatotoxicity 9(26.4%) 1(2.9%) 1(2.9%) -
Cardiac toxicity 2(5.8%) 1(2.9%) - -
Nephrotoxicity 5(14.7%) - - -
Neurotoxicity 4(11.8%) 1(2.9%) - -
Alopecia 12(35.2%) 7 (20.6%) 2(5.8%) -
Fatigue - 11(32.4%) - -
Infection - 4(11.8%) - -
Skin rash - 2(5.8%) - -
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Response
Among the 34 patients ORR was 18% (95% CI, 4.4 - 31.6); 2
(6%) patients demonstrated CR to chemotherapy whereas 4
(12%) patients showed PR (Table 5). Again 9 (26%) of the
patients had SD where the other 19 (56%) patients had PD.
The main sites of recurrence were abdomen and pelvic region
and 7 patients had extra abdominal metastasis. All this pro-
gressive disease patients had 1-3 cycles and only one patient
had 4 cycles of chemotherapy and subsequently switched
over to other treatment after experiencing diseases progres-
sion. A clinical benefit (objective responses + stable disease) of
44% (95% CI, 15.5 - 72.4) was observed in 15 patients within
34 patients.
TABLE 5: Response rate.
Response Patient no.(n=34) Percentage
Complete response(CR) 2 6




Progressive disease 19 56
Stable disease 9 26
Clinical benefit 15 44
Survival and disease progression
After a median follow-up of 3.1 months (range 0.2-21.3
months), median DFS was 17.05 months with a range of 12.8
to 21.3 months (95% CI,-29.1 to 55.2). One patient with CR
who was under our follow-up was dead uneventfully after a
DFS of 21.3 months. Another patient with CR was under
follow-up till her DFS of 12.8 months and then got lost. Again
median RFS was 4.4 months with a range of 2.9 to 21.3
months (95% CI, 0.65-15.8). 32 patients demonstrated disease
progression.
TABLE 6: Time to progression and survival data.
Months
Follow up
Range 0.2 - 21. 3
Median 3.1
Disease free survival (DFS)
Events 2
Range 12.8 - 21. 3
Median 17.05
95% CI -29.1 to 55.2
Relapse free survival (RFS)
Events 6
Range 2.9 - 21.3
Median 4.4
95% CI 0.65 - 15.8
Time to progression (TTP)
Events 32/ 34
Range 0.8 - 2.9
Median 1.25
95% CI 0.98 - 1.4
The median TTP was 1.2 months where the range was 0.8 -
2.9 months (Table 6) and (Figure 1). But obtaining the overall
survival (OS) was not possible as except the 2 patients those
who gained CR, other 32 patients went through different
chemotherapy regimens on being determined with diseases
progression.
FIG. 1: Median TTP
Discussion
Despite the remarkable achievements in the last decades,
most of the patients experienced diseases recurrence and
platinum resistance after the standard treatment of EOC.33 A
variety of chemotherapy agents are being applied for this
purpose and among this OXL and VNR has shown promising
activities against different types of carcinoma.34 Both of these
drugs exhibited the opposite toxicity profile.25, 29 All these
facts made us interested to determine the effects of the com-
bination of these two drugs.
Total 34 patients aged between 32 and 73 years, were heavily
pretreated with various types of platinum based chemother-
apy with a number of 234 cycles following diagnosis at FIGO
stage IIIC, developed platinum resistance and enrolled in our
study with satisfactory inclusion criteria. After a median
interval of 3.6 months from previous platinum based treat-
ment they were further treated with OXL and VNR combi-
nation with a dose of 100 mg/m2 and 30 mg/m2 respectively.
After getting 108 cycles with a median of 3 cycles, ORR was
18% (95% CI, 4.4-31.6) that is 6 patients; 2(6%) with CR and
4 (12%) with PR. SD was seen in 9 (26%) patients and Pro-
gressive diseases were seen in 19 (56%) patients. Out of 34
patients clinical benefit is seen in 15 (44%) of them. Phase I
study of VNR (20-27 mg/m2) and OXL (40-55 mg/m2) on
advanced solid tumors showed an ORR of 24% where CR was
1(4%), PR was 5(20%) and SD was 4 (16%) as a second line
chemotherapy combination.35 Again 21% ORR was observed
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in single agent Phase II study of VNR (30 mg/m2) and 17% in
OXL (median dose of 100 mg/m2).24, 36 In different Phase II
study of VNR in combination like- VNR (25 mg/m2) with
Docetaxel showed an ORR of 23.9%, SD of 34.8%, PD of
30.4% and VNR (30 mg/m2) with PLD had an ORR of 37%,
SD of 10% and PD 53.5%.27, 37 Again, OXL (100 mg/m2) along
with Docetaxel provided an ORR of 37.5% and SD 43.75 %,
OXL (50 mg/m2) with PLD showed an ORR of 31.5% and SD
of 42.1%.4, 38 VNR (30mg/m2) with Gemcitabine combination
showed an ORR of 11% and SD of 24%, PD 65%.39However,
OXL (100 mg/m2) with Gemcitabine had the ORR of 37% and
SD of 41%.40
The median DFS of this regimen was 17.05 months (95% CI,
-29.1 to 55.2) with an optimum of 21.3 months after a median
follow up of 3.1 months. Phase II study of VNR with Docet-
axel showed a median DFS of 13 months.37 Median RFS of the
combination was 4.4 months (95% CI, 0.65 - 15.8) where in
Phase II study of VNR with docetaxel had 5 months and
OXL–Gemcitabine combination showed 6.8 months.37, 40
median TTP of VNR–OXL was 1.25 months (95% CI, 0.98 -
1.4). Median TTP of VNR as a single agent was 3.1 months in
Phase II study but with Docetaxel and PLD it showed 4.5
months and 5.5 months respectively.27, 36, 37 OXL with PLD
showed median TTP of 5.5 months.4
The toxicity profile of drug combination was well tolerable
and reversible. Hematological toxicities were mild, only
1(2.9%) patient had G3 anemia, 2 (5.8%) and 5(14.7%) pa-
tients had G2 leukopenia and neutropenia respectively. G2
febrile neutropenia was observed in 3(8.8%) patients.
Non-hematological toxicity includes mainly nau-
sea-vomiting, diarrhea, constipation, hepatotoxicity, alopecia,
fatigueness and most of them are limited to mild grades.
61.6% patients exhibited alopecia which was up to G2; only 2
(5.8%) patients had G3 alopecia. G2 fatigueness was observed
in 11 (32.4%) patients. Nausea and vomiting were observed in
70.6% patients but mainly G1 (53%). Mild neurotoxicity was
observed in 5 patients and among them only 1(2.9%) was
experiencing G2. By analysis other studies of OXL and VNR it
is seen that toxicity profile is better and similar with most of
the studies (4, 27, 37-40) and can be manageable with con-
servative treatments.
This combination is very uncommon. Since the patients be-
came platinum resistant, this combination is used as an op-
tion. It is observed that when the application of few cycles
could not make any desirable improvement, it led to diseases
progression in all the patients (except for the case of complete
remission) and ultimately patients were switched over to
other kinds of treatment. Since all the patients were alive
during this short period of treatment, the overall survival
could not be determined. The result of the study is proved to
be of an average standard as they are applied on the patients
already treated with 1-3 platinum based chemotherapy reg-
imens. But VNR and OXL when being combined with other
chemotherapy agents, the effect seems to be better than this
combination but the toxicity profile approximately remains
similar with the safe margin.
Conclusion
The Oxaliplatin-Vinorelbine combination is a regimen with a
moderate therapeutic effect but compared to other regimens
of both drugs, the activity is substandard with a tolerable
toxic side effect in patients with recurrent platinum registrant
EOC. However, this retrospective analytical study suggests
the need of further evaluation since it was limited to less
number of patients which might be contributory designing
the future study to evaluate its clinical utility. As such, more
elaborate multicenter, prospective and randomized con-
trolled clinical studies with a large number of patients are
necessary to evaluate its therapeutic and side effects for the
treatment of recurrent and platinum registrant EOC.
Abbreviation
Epithelial ovarian carcinoma (EOC), Vinorelbine (VNR),
Oxaliplatin (OXL), Overall response rate (ORR), Complete
response (CR), Partial response (PR), Stable diseases (SD),
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lapse free survival (RFS), Time to progression (TTP),
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ny-stimulating factor (G-CSF)
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